IOVA Iovance Biotherapeutics, Inc.
USHealthcareAs of 2026-07-02
Why IOVA matters now
Iovance Biotherapeutics, Inc. (IOVA) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.31 with +8.56% on the session and $1.54B in market capitalization; recent performance reads 1-month +13.01% and YTD +43.22%.
The latest financial table shown here is Q1 2026, with revenue of $71.4M, net income of $-79.0M, and EPS of $-0.19. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -21.8%.
The latest indexable market news headline is "Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?" from The Motley Fool.
Additional event context on this page matters because analyst consensus is Buy with a median target of $5.00; recent insider activity includes Puri Raj K. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.27
P/S
4.89
EV/EBITDA
-3.89
DCF Value
$4.06
FCF Yield
-21.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
114.5%
Operating Margin
-127.2%
Net Margin
-123.9%
ROE
-50.2%
ROA
-38.2%
ROIC
-45.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $71.4M | $-79.0M | $-0.19 |
| Q4 2025 | $86.8M | $-71.9M | $-0.15 |
| FY 2025 | $263.5M | $-391.0M | $-1.09 |
| Q3 2025 | $67.5M | $-91.3M | $-0.25 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$4.00
Target (Median)
$5.00
Target Range
$2.00 - $5.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.70
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.